The new HCPCS Level II code for “Injection, tocilizumab-aazg (Tyenne), biosimilar, 1 mg” is Q5135. “These CMS designations are important reimbursement milestones for Tyenne because they ease access ...

LAKE ZURICH, Ill., April 09, 2026--(BUSINESS WIRE)--Fresenius Kabi, a part of Fresenius, and a leading provider of essential medicines and medical technologies, announced today that the Centers for ...

On July 2, 2024, Fresenius Kabi (“Fresenius”) announced the immediate availability of TYENNE (tocilizumab-aazg), in a subcutaneous formulation, in the United States. TYENNE, a biosimilar to ACTEMRA ...

Please provide your email address to receive an email when new articles are posted on . Tyenne (tocilizumab-aazg) is available in a prefilled syringe, pen injector or vial. The biosimilar will launch ...

The US Food and Drug Administration (FDA) has approved the biosimilar tocilizumab-aazg (Tyenne), Fresenius Kabi, the drug's manufacturer, announced today. This is the second tocilizumab biosimilar ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific ...

LAKE ZURICH, Ill., October 29, 2024--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, ...

For TYENNE subcutaneous injection, advise patients to seek immediate medical attention if they experience any symptoms of a hypersensitivity reaction. If anaphylaxis or other hypersensitivity reaction ...